학술논문
P.101 Baseline characteristics/initial safety in RESPOND: phase 4 study of nusinersen in children with SMA who previously received onasemnogene abeparvovec
Document Type
Abstract
Author
Source
In Neuromuscular Disorders October 2022 32 Supplement 1:S86-S86
Subject
Language
ISSN
0960-8966